BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 21663619)

  • 1. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
    Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.
    Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P
    Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
    Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
    Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
    Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
    Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.
    Serrano MJ; Ortega FG; Alvarez-Cubero MJ; Nadal R; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Delgado-Rodriguez M; Solé F; García MA; Perán M; Rosell R; Marchal JA; Lorente JA
    Oncotarget; 2014 Sep; 5(17):7486-97. PubMed ID: 25277187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
    Yang L; Lv Z; Xia W; Zhang W; Xin Y; Yuan H; Chen Y; Hu X; Lv Y; Xu Q; Weng X; Ni C
    Clin Transl Oncol; 2018 Jul; 20(7):912-921. PubMed ID: 29243075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
    Bredemeier M; Kasimir-Bauer S; Kolberg HC; Herold T; Synoracki S; Hauch S; Edimiris P; Bankfalvi A; Tewes M; Kimmig R; Aktas B
    Mol Med Rep; 2017 May; 15(5):2957-2968. PubMed ID: 28358430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis.
    Vardas V; Politaki E; Pantazaka E; Georgoulias V; Kallergi G
    Int J Dev Biol; 2022; 66(1-2-3):277-283. PubMed ID: 34881791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
    Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.